Steven D. Wittlin, MD
Associate Professor of Medicine
Clinical Director of Endocrine/Metabolism Unit
University of Rochester
School of Medicine & Dentistry
William V. Tamborlane, Jr., MD
Professor of Pediatrics
Yale University School of Medicine
New Haven, CT
Charles H. Raine, III, MD
Adjunct Assistant Professor of Medicine
Medical University of South Carolina
Director, Diabetes Control
& Endocrinology Center
Thomas Blevins, MD
Director, Texas Diabetes Endocrinology
Physician CME 2.0
Nurse CE 2.4 Medium
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIANS, NURSES, AND CASE MANAGERS. PHYSICIAN ASSISTANTS AND CERTIFIED DIABETES EDUCATORS QUALIFY FOR CME CREDIT -- SEE CREDIT STATEMENTS, BELOW.
Medical research continues to show, with increasingly persuasive and credible evidence, that tight glycemic control is crucial to the health and well-being of people with diabetes. This has led to clear and compelling guidelines mandating progressively lower targets for HbA1c. Today, insulin pump therapy is widely regarded as the gold standard for adults with Type 1 diabetes. However, pump use in other diabetes populations remains relatively unexplored. In combination with advances in minimally invasive continuous glucose monitoring, pump therapy has the potential to benefit even larger patient populations. This virtual meeting program discusses the advantages and limitations of using insulin pump therapy in patient populations that have previously been considered unusual candidates for this approach. The role of insulin pump therapy in pregnancy, children, adults with Type 2 diabetes, and those who may have latent autoimmune diabetes in adulthood will be discussed by clinicians who have substantial experience in these subjects. Program Developer/Facilitator
. Target Audience
Physicians, nurses, and other healthcare professionals involved in caring for patients with diabetes mellitus.
Upon completion of this educational activity, the participant should be able to:
Assess the challenges and goals of insulin pump therapy during pregnancy.
Discuss the purpose and effects of insulin pump use in Type 2 diabetes.
Describe the term “latent autoimmune diabetes of adulthood” and its treatment options.
Explain the benefits and limitations of using insulin pump therapy in children and adolescents.
Steven D. Wittlin, MD, has served on the advisory boards of Medtronic, Inc., and Novo Nordisk Pharmaceuticals, Inc. He has also received grant or study support from Animas Corporation, Medtronic, Inc., Eli Lilly and Company, and The Sanofi-Aventis Group. He is also on the speakers’ bureaus of Novo Nordisk Pharmaceuticals, Inc., and The Sanofi-Aventis Group. He intends to discuss unapproved/investigative uses of pharmacologic products or surgical devices.
William V. Tamborlane, Jr., MD, has received consultant fees, grant/research support, and honoraria from Medtronic, Inc., and Novo Nordisk Pharmaceuticals. He does not intend to discuss unapproved/investigative uses of pharmacologic products or surgical devices.
Charles H. Raine, III, MD, is on the advisory board of Medtronic, Inc. He is also on the speakers’ bureaus of Aventis Pharmaceuticals, Inc., and Novo Nordisk Pharmaceuticals, Inc. He has also served as a consultant for Disetronic Medical Systems, Inc. He does not intend to discuss unapproved/investigative uses of pharmacologic products or surgical devices.
Thomas Blevins, MD, is on the speakers’ bureaus of Bristol-Myers Squibb Company, Eli Lilly and Company, Merck-Aventis, Pfizer, Inc., and Sanofi-Synthélabo, Inc. He does not intend to discuss unapproved/investigative uses of pharmacologic products or surgical devices.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's commission on Accreditation. AKH Inc. designates this activity for 2.4 contact hours of continuing nursing education credit.
This activity has been approved for 2 hours of continuing education credit by the Commission for Case Manager Certification.
Certified Diabetes Educators:
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (www.ncbde.org). NCBDE does not approve continuing education. AKH Inc. is on the NCBDE List of Approved Providers.
AAPA accepts Category I CME credit for the PRA from organizations accredited by the ACCME. All programs on cmecorner.com that carry ACCME Category I CME credit are acceptable toward the PA Category I (Preapproved) CME requirement.
PAs requesting credit should check the "Physician" box on the post-test.
All participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Commercial Support Statements
This program is supported by an educational grant from Medtronic Diabetes.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking on "Slides" on this screen will bring you to instructions to turn off pop-up blockers and begin the program presentation, which will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to register and access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CE certificate.
None of the contents may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, AKH Inc., Medical Communications Media, or Medtronic Diabetes. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.